Five recent developments in psoriasis

Research presented at the European Academy of Dermatology and Venereology Congress showing that Cosentyx was superior to placebo at 12 weeks for clearing moderate-to-severe scalp psoriasis was among recent developments reported on Healio.com/Dermatology.

Other developments included findings that patients with moderate-to-severe psoriasis who were treated with Xeljanz saw improvements in health-related quality of life over 52 weeks, with rapid improvement in pruritus:

Cosentyx efficacious at 12 weeks for clearing scalp psoriasis

Cosentyx was superior to placebo at 12 weeks for clearing moderate-to-severe scalp psoriasis, according to research presented at the European Academy of Dermatology and Venereology Congress in Vienna.

Mark Lebwohl

Mark Lebwohl, MD, of Mount Sinai Hospital, New York, and colleagues conducted a double-blind, placebo-controlled study of 102 patients with moderate-to-severe scalp psoriasis. Read more

Tildrakizumab demonstrates efficacy in moderate-to-severe plaque psoriasis

Tildrakizumab, an investigational IL-23p19 inhibitor, demonstrated efficacy in treating moderate-to-severe chronic plaque psoriasis in two phase 3 trials at week 12, with continued improvement through week 28, according to data presented at the European Academy of Dermatology and Venereology Congress in Vienna.

“For patients with psoriasis, their condition is always top of mind and they struggle on a daily basis with the often debilitating effects of this chronic condition,” study researcher Kristian Reich, MD, professor of dermatology at the Georg-August-University Göttingen and inflammation specialist at the Dermatologikum Hamburg in Germany, stated in a press release from Sun Pharma. Read more

Xeljanz improved pruritus, QoL up to 1 year in patients with psoriasis

Patients with moderate-to-severe psoriasis who were treated with Xeljanz saw improvements in health-related quality of life over 52 weeks, with rapid improvement in pruritus, according to research published in the Journal of the American Academy of Dermatology.

“Plaque psoriasis is a chronic disease therefore providing long-term improvement in [health-related quality of life] is a key goal of therapy,” Steven R. Feldman, MD, PhD, of Wake Forest School of Medicine, Winston-Salem, North Carolina, and colleagues wrote. Read more

Survey finds more than half of patients with psoriasis to do not achieve clear skin

In a large global survey of patients with psoriasis, 57% of respondents reported not achieving the treatment goal of clear skin, according to research presented at the European Academy of Dermatology and Venereology Congress in Vienna.

There were more than 8,300 people from 31 countries who took part in the survey, which was a partnership between Novartis, which initiated and funded the survey, and patient organizations around the world, according to a press release. Read more

Mortality lower for patients hospitalized for atopic dermatitis compared with psoriasis

Patients who were hospitalized for atopic dermatitis had a significantly lower 10-year mortality compared with patients hospitalized for psoriasis, but an increased mortality compared with the general population, according to recently published study results.

Researchers used Danish nationwide registers between 1996 and 2002 to study 576 patients hospitalized with atopic dermatitis and 951 patients hospitalized with psoriasis, and 5,760 healthy controls. Read more